Abstract 1396: FGFR1-induced radioresistance of Panc02 pancreatic tumor cells is decreased by SSR128129 treatment in vitro and in vivo

We have previously established the important role of FGF-2 pathways in tumor cell radioresistance. Although radiotherapy is commonly used in the treatment of pancreatic carcinomas which are known to express FGF and FRGFR, the role of FGFR pathways in radioresistance of pancreatic tumor has not yet been studied. We established a new syngenic mouse model of orthotopic pancreatic xenograft of Panc02 cells transfected with hFGFR1-receptor (Panc02-FGFR1). Whereas the in vitro radioresistance of the parental cell line (Panc02) was not affected by the addition of the specific FGF-receptor antagonist SSR128129, Panc02-FGFR1 radioresistance was significantly decreased by treating cells with SSR128129 (1 µM) 4 hours before irradiation (mean inactivation dose [MID] was 6.1±0.2 Gy in control PancO2-FGFR1 versus 4.2±0.2 Gy in SSR128129 treated cells, P